pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Sarclisa
drug · antibody
save

isatuximab

pre_registrationupdated 6mo ago
by $SNY Sanofi🔗 ChEMBL
community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and multiple myeloma and 10 investigational indications.

targets

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1

all catalysts(0)

nothing on the calendar yet

Trials studying isatuximab

  • phase3To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myelomanot yet recruitingn=750
  • phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatmentsrecruitingn=317
  • phase2Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patientsrecruitingn=61
  • phase2Isatuximab in Combination With Novel Agents in RRMM - Master Protocolrecruitingn=258
  • phase2Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myelomaactive not recruitingn=30
  • phase3SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMMactive not recruitingn=531
  • phase2Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myelomarecruitingn=62
  • phase2Isatuximab in Patients With Monoclonal Gammopathy of Renal Significanceactive not recruitingn=12

News(2)

  • Unlocking cell surface protein research with site-specific labeling
    Applications in flow cytometry, cell sorting, target validation, and therapeutic discovery
    biospace · 2mo ago
  • STAT+: Pharmalittle: We’re reading about an RFK Jr. push against psychiatric meds, a Sanofi blood cancer drug, and more
    U.S. health secretary Robert F. Kennedy Jr. is pressing forward with his effort to help Americans stop taking SSRI antidepressants
    stat · 4mo ago
brand
Sarclisa
trade names
Sarclisa
generic
isatuximab-irfc
MOA
Lymphocyte differentiation antigen CD38 inhibitor
indication
Refractory Multiple Myeloma
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?